Tricida Announces Multiple Data Presentations to Be Given at the Virtual National Kidney Foundation 2021 Spring Clinical Meetings
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical firm, announced its participation in the National Kidney Foundation 2021 Spring Clinical Meetings from April 6-10, 2021. The company will present findings related to metabolic acidosis and chronic kidney disease (CKD). Key presentations include studies showing the link between low serum bicarbonate levels and mortality in kidney transplant recipients, as well as the benefits of increasing serum bicarbonate in CKD patients. Tricida's investigational drug, veverimer, aims to treat metabolic acidosis in CKD patients and is currently undergoing clinical trials.
- Tricida is presenting multiple studies at a prominent medical conference, which may enhance visibility and credibility.
- Data presented could support the efficacy and importance of veverimer in treating metabolic acidosis, potentially attracting interest from investors and healthcare professionals.
- Veverimer is still in clinical trials, indicating uncertainty around its FDA approval and commercial viability.
- The company operates in a competitive market with no FDA-approved treatments for chronic metabolic acidosis, posing a challenge for market entry.
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that multiple presentations on the impact of metabolic acidosis and CKD and data on veverimer will be given at the National Kidney Foundation 2021 Spring Clinical Meetings taking place from April 6 to 10, 2021.
Data from Tricida-sponsored studies on the impact of metabolic acidosis and CKD will include the following:
| Title: | Low Serum Bicarbonate is Associated with Excess Mortality in Kidney Transplant Recipients |
| Author: | V. Mathur et al. |
| Link: | View poster here |
| Poster #: | 275 |
| Title: | Low Serum Bicarbonate is Associated with Graft Failure and Major Cardiovascular Outcomes in Kidney Transplant Recipients |
| Author: | V. Mathur et al. |
| Link: | View poster here |
| Poster #: | 276 |
| Title: | Increasing Serum Bicarbonate Is Associated with Reduced Risk of Adverse Kidney Outcomes in Patients with CKD and Metabolic Acidosis |
| Author: | N. Tangri et al. |
| Link: | View poster here |
| Poster #: | 279 |
| Tricida will also present data on veverimer: | |
| Title: | Evaluation of Potential Physicochemical Interactions of Orally Administered, Non-absorbed Ion-exchange Resins with Veverimer |
| Author: | S. Tabakman et al. |
| Link: | View poster here |
| Poster #: | 278 |
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows progression of CKD in patients with metabolic acidosis and CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.
For more information about Tricida, please visit www.Tricida.com.
Contact:
Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com
Source: Tricida, Inc.
FAQ
What presentations is Tricida conducting at the National Kidney Foundation 2021 Spring Clinical Meetings?
When is the National Kidney Foundation 2021 Spring Clinical Meetings?
What is the focus of Tricida's investigational drug veverimer?
What is the significance of Tricida's studies presented at the conference?
What is the current status of veverimer's clinical trials?
